Active and higher intracellular uptake of 5-aminolevulinic acid in tumors may be inhibited by glycine

J Invest Dermatol. 1999 May;112(5):723-8. doi: 10.1046/j.1523-1747.1999.00579.x.

Abstract

Topical 5-aminolevulinic acid is used for the fluorescence-based diagnosis and photodynamic treatment of superficial precancerous and cancerous lesions of the skin. Thus, we investigated the kinetics of 5-aminolevulinic acid-induced fluorescence and the mechanisms responsible for the selective formation of porphyrins in tumors in vivo. Using amelanotic melanomas (A-Mel-3) grown in dorsal skinfold chambers of Syrian golden hamsters fluorescence kinetics were measured up to 24 h after topical application of 5-aminolevulinic acid (1%, 3%, or 10%) for 1 h, 4 h, or 8 h by intravital microscopy (n = 54). Maximal fluorescence intensity in tumors after 1 h application (3% 5-aminolevulinic acid) occurred 150 min and after 4 h application (3% 5-aminolevulinic acid) directly thereafter. Increasing either concentration of 5-aminolevulinic acid or application time did not yield a higher fluorescence intensity. The selectivity of the fluorescence in tumors decreased with increasing application time. Fluorescence spectra indicated the formation of protoporphyrin IX (3% 5-aminolevulinic acid, 4 h; n = 3). The simultaneous application of 5-aminolevulinic acid (3%, 4 h) and glycine (20 microM or 200 microM; n = 10) reduced fluorescence in tumor and surrounding host tissue significantly. In contrast, neither decreasing iron concentration by desferrioxamine (1% and 3%; n = 10) nor inducing tetrapyrrole accumulation using 1, 10-phenanthroline (7.5 mM; n = 5) increased fluorescence in tumors. The saturation and faster increase of fluorescence in the tumor together with a reduction of fluorescence by the application of glycine suggests an active and higher intracellular uptake of 5-aminolevulinic acid in tumor as compared with the surrounding tissue. Shorter application (1 h) yields a better contrast between tumor and surrounding tissue for fluorescence diagnosis. The additional topical application of modifiers of the heme biosynthesis, desferrioxamine or 1,10-phenanthroline, however, is unlikely to enhance the efficacy of topical 5-aminolevulinic acid-photodynamic therapy at least in our model.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminolevulinic Acid / pharmacokinetics*
  • Animals
  • Biological Transport / drug effects
  • Cricetinae
  • Deferoxamine / pharmacology
  • Diffusion Chambers, Culture
  • Glycine / pharmacology*
  • Male
  • Melanoma, Amelanotic / metabolism*
  • Mesocricetus
  • Neoplasm Transplantation
  • Phenanthrolines / pharmacology
  • Protoporphyrins / biosynthesis
  • Skin Neoplasms / metabolism*
  • Spectrometry, Fluorescence

Substances

  • Phenanthrolines
  • Protoporphyrins
  • Aminolevulinic Acid
  • protoporphyrin IX
  • Deferoxamine
  • Glycine
  • 1,10-phenanthroline